Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028

Praxis Precision Medicines (NASDAQ: PRAX) reported a Q2 2026 net loss of $83.7 million, compared with $71.1 million a year earlier, while basic and diluted loss per share narrowed to $2.87 from $3.31. Higher operating expenses widened the dollar loss, but increased other income and a larger weighted-average share count helped reduce the loss reported per share. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, 2026.

Core financial results

Praxis’ total operating expenses increased approximately 27% to $96.9 million. G&A expense more than doubled, while R&D expense rose approximately 10% as the company continued clinical development and prepared commercial infrastructure for its late-stage programs.

Other income increased by $8.2 million to $13.2 million, partially offsetting the higher operating loss. As a result, the net loss increased by $12.6 million, less than the $20.8 million increase in operating expenses.

A wider net loss came with a narrower per-share loss

Praxis’ weighted-average common shares outstanding increased to 29.1 million from 21.5 million, or approximately 36%. That larger denominator caused the loss per share to narrow even though the company’s total net loss increased.

The EPS change therefore did not reflect improved company-level profitability. Both the operating loss and net loss widened, with increased other income providing only a partial offset to higher expenses.

Expense mix and cash runway

The $6.4 million increase in R&D expense reflected $6.7 million of additional Solidus platform spending, $4.4 million of higher personnel costs and $1.8 million of increased indirect costs. These increases were partially offset by a $6.5 million reduction in Cerebrum-related expenses.

G&A expense rose by $14.4 million, primarily because professional expenses increased by $7.2 million and personnel-related costs increased by $6.3 million. This higher expense base comes as Praxis hires commercial and medical teams and builds systems, inventory and distribution capabilities ahead of potential product approvals.

Cash, cash equivalents and marketable securities increased to approximately $1.4 billion from $926.1 million at December 31, 2025. The $447.8 million increase primarily came from the January 2026 follow-on public offering and interest income, partially offset by cash used in operations. Praxis expects these resources to fund operations into 2028.

Pipeline and regulatory progress

Ulixacaltamide

The FDA review of ulixacaltamide HCl for essential tremor is proceeding with a January 29, 2027 PDUFA target date. At the mid-cycle meeting, the FDA identified no major safety or efficacy concerns to date and said it does not plan to hold an advisory committee meeting.

Praxis is building commercial infrastructure, including marketing and disease-education programs, physician targeting, medical information capabilities, inventory and an established distribution network. The company also began a July 2026 collaboration with Remagine Labs to develop a transdermal ulixacaltamide formulation.

Relutrigine

The FDA extended relutrigine’s review after determining that additional sensitivity analyses submitted by Praxis constituted a major amendment. The new PDUFA target date is December 27, 2026. As with ulixacaltamide, the FDA identified no major safety or efficacy concerns at the mid-cycle meeting and does not plan an advisory committee meeting.

FDA Bioresearch Monitoring inspections related to both applications were completed without any Form FDA 483 observations. Both applications nevertheless remain subject to final regulatory decisions.

The EMERALD study of relutrigine in broader developmental and epileptic encephalopathies enrolled approximately 200 patients, exceeding its target and covering more than 50 genetically defined etiologies. Topline results are expected in Q4 2026. If the initial relutrigine application is approved and EMERALD is positive, Praxis plans to use the study as the basis for a supplemental application in 2027.

Vormatrigine and elsunersen

The POWER1 trial of vormatrigine did not meet its primary endpoint of reducing monthly focal seizure frequency at Week 12. It did meet a secondary endpoint measuring the number of patients who achieved at least a 50% reduction in seizure frequency. Praxis plans to restart POWER2 and initiate POWER3 in Q4 2026 based on lessons from POWER1.

Elsunersen received FDA Breakthrough Therapy Designation following positive EMBRAVE Part A results, becoming Praxis’ third such designation in 12 months. Enrollment in the registrational EMBRAVE3 study is progressing, with topline results expected in 2027.

Recent insider transactions

The supplied six-month insider summary reports 17 purchase transactions totaling 48,562 shares and one sale totaling 11,600 shares, resulting in net purchases of 36,962 shares. The latest records are dominated by stock awards and a gift, which should be distinguished from open-market purchases or sales.

These transactions describe reported insider activity but do not, by themselves, establish insiders’ views on Praxis’ outlook.

Risks investors need to monitor

• Pending regulatory decisions: The FDA’s lack of major safety or efficacy concerns to date and decision not to convene advisory committees do not constitute final approval of ulixacaltamide or relutrigine.
• Relutrigine review extension: The major amendment moved the PDUFA date to December 27, 2026, highlighting potential timing and regulatory-execution risk.
• Vormatrigine efficacy risk: POWER1 missed its primary endpoint. The value of the program now depends partly on whether changes informed by that trial produce better results in POWER2 and POWER3.
• Higher spending before potential launches: R&D and G&A expenses increased, widening the net loss. Praxis has funding into 2028, but continued development and commercialization preparations will consume cash.
• Clinical readout uncertainty: EMERALD results will affect relutrigine’s potential expansion into broader DEEs, while EMBRAVE3 remains important to elsunersen’s registrational path.

Summary

Praxis’ Q2 2026 results reflected rising development and corporate spending as two lead applications moved closer to FDA decisions and commercial preparations accelerated. The company’s approximately $1.4 billion liquidity position provides runway into 2028, but near-term progress depends on the relutrigine and ulixacaltamide reviews, the Q4 EMERALD readout and execution of the revised vormatrigine development plan.